Glucotrack SEC Filings

Glucotrack, Inc. filed a 424(b)(3) prospectus covering the resale of up to 20,060,000 shares of common stock by Sixth Borough Capital Fund, LP. The registration includes up to 20,000,000 Purchase Shares that the company may sell to Sixth Borough under a committed equity facility and up to 60,000 Commitment Shares issuable upon exercise of pre-funded warrants granted as a fee.

The company is not selling securities in this prospectus and will not receive proceeds from Sixth Borough’s resales. Glucotrack may receive up to $20.0 million from its own future sales of Purchase Shares to Sixth Borough after the registration is effective and other conditions are met, with pricing determined by formulas in the purchase agreement.

Sales are subject to limits, including a Nasdaq Exchange Cap of 179,792 shares (19.99%) unless stockholder approval is obtained or the Average Price equals or exceeds $4.63, and a 4.99% Beneficial Ownership Cap. As of October 8, 2025, shares outstanding were 910,688; the registered shares represent approximately 2,203% of that baseline, and their resale could pressure the stock price. Sixth Borough is deemed an underwriter for these resales. Net proceeds to Glucotrack from any sales to Sixth Borough, if made, are for working capital and general corporate purposes.

Glucotrack, Inc. filed a Form 8-K to report that it issued a press release on October 29, 2025. The company furnished this press release as Exhibit 99.1 under Item 7.01, Regulation FD Disclosure. The filing does not add financial statements or describe specific transaction details.

Glucotrack, Inc. furnished a press release under Item 7.01 (Regulation FD Disclosure) in a Form 8-K. The company attached the press release as Exhibit 99.1.

The company states the information provided under Item 7.01, including Exhibit 99.1, is furnished and not deemed “filed” under the Exchange Act unless specifically indicated otherwise.

Glucotrack, Inc. filed an amended S-1 registration describing an equity offering tied to a committed purchaser, Sixth Borough, and disclosing recent capital structure and per-share metrics. The prospectus shows a proposed public offering with an assumed price of $7.45 per share and a committed purchase structure that could issue up to 60,000 Commitment Shares on exercise of pre-funded warrants issued to Sixth Borough as payment for its purchase commitment.

Reported historical metrics are fragmentary but include multiple periods of negative results: extremely large reported net losses per share in some earlier small-period columns (e.g., figures like $68.44 and $4,106 appear) and more recent weighted-average shares and period-end common shares (for example, 10,160,725 weighted average shares in one period and 25,585,853 common shares at period end in another). The filing shows net tangible book value per share after the offering of $7.26, a decrease per share attributable to the offering of $0.29, and dilution to new investors of $0.19. Estimated offering proceeds scenarios reference aggregate amounts of $20,000,000 at various assumed prices.

Glucotrack, Inc. (GCTK) Form 3 shows that Brendel Victoria Carr is listed as a director and filed an initial Section 16 disclosure for the 05/22/2025 event date. The filing states no securities are beneficially owned by the reporting person and includes an exhibit appointing a power of attorney for signature. This indicates the director currently holds no equity position disclosed under Section 16.

Insider transactions by Director Andrew K. Balo increased his reported beneficial stake in Glucotrack, Inc. (GCTK) through several non‑derivative share grants and a stock option award. The filing records three non‑derivative stock acquisitions on 03/25/2025, 07/11/2025 and 10/03/2025 that cumulatively bring his reported direct beneficial ownership to 4,692 common shares. The filing also shows a stock option granted on 10/03/2025 to buy 4,055 shares at an exercise price of $7.4, exercisable on 10/03/2025 and expiring on 10/03/2035. The report states option vesting starts each July 1 and vests monthly over 12 months, subject to continued service. All reported figures reflect three disclosed reverse stock splits completed in 2024, 02/25/2025, and 06/13/2025.

Glucotrack, Inc. director Luis Malave reported multiple stock option and common stock acquisition transactions across 2025 that increase his direct ownership. The filing shows three non‑derivative common stock acquisitions: 35 shares on 03/25/2025, 1,200 shares on 07/11/2025, and 463 shares on 10/03/2025, bringing his total direct common shares to 4,058. The filing also records a derivative transaction on 10/03/2025 for a stock option exercisable at $7.4 covering 4,055 underlying shares that expire on 10/03/2035, leaving 4,055 options held directly.

The reported grants vest monthly over 12 months starting each July 1, subject to continued service. The filing notes multiple reverse stock splits in 2024 and 2025 and states all figures reflect those splits. The report was signed by an attorney‑in‑fact on 10/07/2025.

Glucotrack, Inc. (GCTK) director Erin Catherine Carter reported multiple equity awards and exercises that increased her direct common stock holdings and option position. On 03/25/2025 she was recorded as acquiring 32 shares, followed by 1,000 shares on 07/11/2025 and 386 shares on 10/03/2025, bringing total directly held common stock to 2,148 shares after those transactions. The filing also shows an option grant exercisable beginning 10/03/2025 for 4,055 shares with an exercise price of $7.4 and an expiration in 10/03/2035. The Form 4 notes standard vesting that begins on July 1 of the applicable year and vests monthly over 12 months, and it discloses that reported share figures reflect a series of reverse stock splits implemented in 2024, 02/25/2025, and 06/13/2025.

Glucotrack, Inc. (GCTK) reported an insider transaction on Form 4. The company’s Chief Executive Officer and director received 42 shares of common stock on 03/25/2025, issued upon achievement of a milestone under an October 7, 2022 Intellectual Property Purchase Agreement. The transaction is coded J (other).

Following this issuance, the reporting person beneficially owns 339 shares, held directly. The company notes that all figures reflect reverse stock splits implemented on 05/17/2024, 02/25/2025, and 06/13/2025.